Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Alquati

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1997
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable diseaseA Bottini, A Berruti, M Tampellini, et al.
Anticancer Research|September 1, 1996
Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumoursA Bottini, A Berruti, A Bersiga, et al.
British Journal of Cancer|September 11, 2003
Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancerA Bottini, A Berruti, M P Brizzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclinesA Berruti, P Sperone, A Bottini, et al.
Breast Cancer Research and Treatment|January 5, 2002
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable diseaseC Fiorentino, A Berruti, A Bottini, et al.
British Journal of Cancer|November 17, 2001
Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancerA Bottini, A Berruti, A Bersiga, et al.
Endocrine-Related Cancer|June 11, 2005
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trialA Bottini, A Berruti, M P Brizzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patientsA Bottini, A Berruti, A Bersiga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trialL Dogliotti, A Berruti, T Buniva, et al.
International Journal of Oncology|July 17, 1998
Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patientsA Bottini, A Berruti, A Bersiga, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1997
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable diseaseA Bottini, A Berruti, M Tampellini, et al.
Anticancer Research|September 1, 1996
Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumoursA Bottini, A Berruti, A Bersiga, et al.
British Journal of Cancer|September 11, 2003
Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancerA Bottini, A Berruti, M P Brizzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclinesA Berruti, P Sperone, A Bottini, et al.
Breast Cancer Research and Treatment|January 5, 2002
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable diseaseC Fiorentino, A Berruti, A Bottini, et al.
British Journal of Cancer|November 17, 2001
Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancerA Bottini, A Berruti, A Bersiga, et al.
Endocrine-Related Cancer|June 11, 2005
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trialA Bottini, A Berruti, M P Brizzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2000
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patientsA Bottini, A Berruti, A Bersiga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trialL Dogliotti, A Berruti, T Buniva, et al.
International Journal of Oncology|July 17, 1998
Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patientsA Bottini, A Berruti, A Bersiga, et al.
Pageof 3